Abstract submissions must be received by 30 November 2024 for consideration.
Abstract SubmissionTimeline
-
Submission Deadline
30 November 2024
Last day to submit abstracts, submission site closes at 23:59 CET
-
Final PDF Poster Submission Date
09 May 2025
Deadline for final printable PDF submission
Each abstract must include the following information to be considered:
- Presentation Title
- Presenter's Name And Contact Details
-
Presenter's Biography
(Approx. 100 words) -
Additional Speakers
(If applicable) - Key objectives of topic
-
2-3 Paragraph Abstract, Summarizing the Topic
(Max 300 words)
General Information
Abstract submitters may submit up to two entries for consideration.
All presentations must be free of commercial intent. Incomplete proposals will not be considered.
Call for Abstracts/Case Studies
Dear Colleague,
We would like to warmly invite you to submit a paper or poster abstract for presentation at the PDA Virus Conference 2025 which will take place on 24-25 June 2025 in Gothenburg, Sweden.
This conference will be part of the PDA Innovative Therapies Summit 2025, alongside the PDA Advanced Therapy Medicinal Products Conference 2025, which will take place on 26-27 June 2025, at the same venue.
Abstracts must be non-commercial in nature, describing new developments or work that significantly contributes to the body of knowledge relating to virus safety and all related aspects as stated below.
The Scientific Program Planning Committee will review all proposals carefully and consider podium and poster contributions. We look forward to receiving your topic proposal!
Sincerely,
The Co-Chairs
Types of Submissions
Podium
- Approx. 20-minute oral presentation, to be made part of a larger session
- One presenter per podium talk. Additional on-site presenters and on-site poster presenters are required to pay appropriate conference registration fees.
Poster
Accepted posters will:
- Be displayed in the exhibit hall and might be a part of the guided poster walk
Get the Attention you deserve!
Maximize your visibility by contributing a podium or poster presentation at PDA Virus Conference 2025. Leverage this unique opportunity to highlight your work at the event. Posters will be available online post-event.
Topics we are looking for:
- 1. Regulatory Updates
- International Perspectives
- Global Pharmacopoeia and Guidance Chapters
- Implementation of ICH Q5A R2 Guideline
- Regulatory Requirements for Virus Safety Testing and Virus Clearance Studies
- Impact of Regulatory Requirements on Pharmaceutical Industry
- Inclusion of Next Generation Sequencing in Regulatory Submissions
- 2. Current and Emerging Viruses
- Hepatitis E Virus
- Parvoviruses
- COVID-19
- Zika
- West Nile
- Swine Flu/Avian Flu
- Measles
- MERS
- Ebola
- Mpox
- Circovirus
- Zoonoses
- 3. Virus Safety of Starting and Raw Materials
- Risk Assessment
- Virus-Like Particles
- Case Studies for Media Treatment
- New Threats to Human Plasma
- Cell Culture Media Treatment/Cell Substrate Safety
- Raw Materials
- Material Selection
- Substances of Human Origin and Animal-Derived Material
- Supplier Audits and Qualification
- Cell-Sorting Antibodies
- Serum and Trypsin
- Antibody Drug Conjugates
- Adventitious Viruses/Adventitious Agents
- Prevention of Contamination
- Utilization of Prior Knowledge
- 4. Viral Safety in Manufacturing
- Risk Management
- Biopharmaceuticals
- Plasma-Derived Medicinal Products
- Viral Vaccines
- Irradiation (Gamma, Electrons, X-Rays)
- Inactivation
- Removal
- Filtration/Nanofiltration
- Prion-Specific Filtration Methods
- Viral Clearance
- Down-Stream Processes/Chromatography
- Sustainable Detergents
- Precipitation
- Continuous Manufacturing
- Platform Approach
- Technical Developments/Innovation, Emergent Technology
- Analytical Methods
- Integrated Recycling Process
- Reduction of Wastewater
- Waste Prevention and Handling
- Environmental Protection
- Recycling Economy
- 5. Virus Testing
- Virus Detection Methods
- Virus-Like Particles
- Developments of New Detection Methods
- Technical Operation of Next Generation Sequencing Platforms, e.g., Automation, Time to Result and Validation
- Next Generation Sequencing and Bioinformatics
- Targeted versus Non-Targeted Next Generation Sequencing
- Product-Enhanced Reverse Transcriptase Assay
- Nucleic Acid-Based Methods
- Digital-Droplet Polymerase Chain Reaction
- Model Organisms, Equipment, and Conditions
- Replacement of Animal/In-Vivo Tests and 3R Initiative
- Cell-Based Assays/Hepatitis E Virus Infectivity Assay
- Emerging and Hard-to-Detect Viruses
- Transmission Electron Microscopy
- Application of Artificial Intelligence
- 6. Viral Safety of ATMPs
- Human Platelet Lysates and Sera
- Viral Vectors/Standards for Vectors
- Virus Panels/Virus Selection
- Virus Safety of Cell Lines
- Helper Virus Production
- Viral Clearance
- Viral Vector Purification Process
- Xenogeneic Cells Used as Feeder Layer or Therapeutic Substance
- Case Studies for Cell and Gene-Based Medicinal Products
- Extracellular Vesicles
- Virus Reduction Studies
- Transplantation and Xenotransplantation
- Application in Medical Devices
- 7. TSE Contamination and Risk Mitigation
- Raw Materials
- Blood Products
- Cell-Based Products
- Cell Substrates
- Infectability of Cell Substrates
- New Concepts for Testing and Identification
- Inactivation Strategies and Equipment
- 8. Aspects of Food and Waterborne Virus Safety
- Norovirus-Related Diseases
- Rotavirus-Related Diseases
- Identification of Viruses in Food Matrixes
- Cultured Meat Products
- Transmission Pathways
- Risk Assessments
- 9. Virus Reduction Studies
- Virus Safety Strategies
- Usage of Prior Knowledge
- Design of Studies
- Design of Experiments Studies
- Platform Validation
- Mechanism of Action of Virus Removal/Inactivation
- Robustness of Specific Unit Operations
- Identification of Critical Process Parameters
- Spike Preparations
- Scalability of Study Design and Study Results
- Sanitization of Chromatographic Equipment
- Columns Including Virus-Carry-Over Studies
- Impact of Virus Spike Quality
- Developments in Laboratory Automation
- Viral Reduction in Alternative Cell Types
Poster Information
All posters will be printed by PDA and displayed as part of the exhibition.
Please send your final printable PDF file and poster title to [email protected].
Important
Poster presenters are required to pay a full conference registration fee.
Join our guided poster walk in our exhibition hall and gain more visibility. You will have the chance to engage with our poster audience!
Poster Display Dimensions
Please find the PDF dimension requirements below:
Exhibition and Sponsorship Opportunities
PDA is seeking vendors who provide products/services in support of this conference. Space on-site is limited and is on a first-come, first-serve basis.
Exhibition: 24-25 June 2025
To reserve your space, please contact Christopher Haertig at [email protected].